As payers have been increasingly impacted by rising drug costs, they have become more creative in plan design by introducing different copay tiers and member incentives to change drug purchasing behavior, say industry watchers.
As payers have been increasingly impacted by rising drug costs, they have become more creative in plan design by introducing different copay tiers and member incentives to change drug purchasing behavior, say industry watchers.
"As pharmacy costs have risen and new products have entered the market-in particular over-the-counter [OTC] and specialty products-and more blockbuster drug classes have generic alternatives, payers are adding additional copay tiers or even waiving copays to achieve desired changes in member behavior," says Dave Borden, principal and co-owner, Pharmaceutical Strategies Group LP (PSG), Irving, Texas.
"We are seeing increasing use of four-tier and five-tier copay plans," Borden says. "A fourth tier is most often used to introduce additional cost sharing to certain high-cost agents. Often these are specialty/bio-tech drugs or in some cases, drugs that have cheap alternatives, and payers are pushing utilization out of higher cost drugs into the lower cost alternatives."
PacificSource Health Plans, a non-profit plan in Eugene, Ore., doesn't offer HMO plans, but the bulk of its copays are four-tier designs, "where specialty drugs have a different copay structure from all the other drugs," says Dennis Rogers, RPh, director of pharmacy services. "The trend is toward reducing copays for generics and addressing specialty drugs separately from the other drugs."
INCENTING MEMBERS
PSG has seen a significant increase in the use of copay waiver or amnesty programs to incent members to try select OTC products, such as OTC PPIs and NSAs, or to switch from a branded product for which there is no direct generic alternative, to a generic for another branded product in that drug class that is therapeutically equivalent.
Another evolution in design is the introduction of coinsurance, often with minimum and maximum copays by tier. "The goal is to reduce the impact of leveraging on drug trend that occurs with flat dollar copays, as well as to help members understand the true cost of a prescription drug with the hope they will make more thoughtful purchasing decisions," Borden says.
-Tracey Walker
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More